Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): A randomised clinical trial

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 3, 2015, Pages 181-190

  de Zeeuw, Dick ^a   Anzalone, Deborah A ^b   Cain, Valerie A ^b   Cressman, Michael D ^c   Heerspink, Hiddo J Lambers ^a   Molitoris, Bruce A ^d   Monyak, John T ^b   Parving, Hans Henrik ^e,f   Remuzzi, Giuseppe ^g   Sowers, James R ^h   Vidt, Donald G ⁱ  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

^c Late Stage Developmental Services Covance Inc   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h UNIVERSITY OF MISSOURI   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATININE; PROTEIN; ROSUVASTATIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; LIPID; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ADULT; ARGENTINA; ARTICLE; BRAZIL; BULGARIA; CANADA; CONTROLLED STUDY; CREATININE URINE LEVEL; DENMARK; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FRANCE; HUMAN; HUNGARY; INSULIN DEPENDENT DIABETES MELLITUS; ITALY; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEXICO; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; ROMANIA; UNITED STATES; UNSPECIFIED SIDE EFFECT; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; DIABETES COMPLICATIONS; DIABETIC NEPHROPATHIES; DOSE RESPONSE; DRUG EFFECTS; EUROPE; KIDNEY; MULTICENTER STUDY; NORTH AMERICA; SOUTH AMERICA; URINE;

ADULT; ANALYSIS OF VARIANCE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CREATININE; DIABETES COMPLICATIONS; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; KIDNEY; LIPIDS; NORTH AMERICA; PROTEINURIA; PYRIMIDINES; PYRROLES; SOUTH AMERICA; SULFONAMIDES;

EID: 84924081459     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70246-3     Document Type: Article

References (29)

1. Gansevoort RT, van der Heij B, Stegeman CA, et al. Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future?. Kidney Int Suppl 2004, 92:S7-S10.
2. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.
3. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869. RENAAL Study Investigators.
4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860. Collaborative Study Group.
5. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
6. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359-364.
7. de Zeeuw D, Lambers Heerspink HJ, Gansevoort RT, Bakker SJL How to improve renal outcome in diabetes and hypertension- the importance of early screening for and treatment of microalbuminuria. Eur Nephrol 2009, 3:13-15.
8. Collins AJ, Foley RN, Herzog C, et al. United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis 2009, 53(suppl 1):S1-S374.
9. Campese VM, Park J HMG-CoA reductase inhibitors and the kidney. Kidney Int 2007, 71:1215-1222.
10. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008, 336:645-651.
11. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
12. Haynes R, Lewis D, Emberson J, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol 2014, 25:1825-1833. SHARP Collaborative Group.
13. Levey AS, Greene T, Kusek JW, Beck GL A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000, 11:155A. MDRD Study Group.
14. Grubb A, Nyman U, Björk J, et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the Modification of Diet in Renal Disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 2005, 51:1420-1431.
15. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009, 15. CD007784.
16. Savarese G, Musella F, Volpe M, Paneni F, Perrone-Filardi P Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. Int J Cardiol 2013, 167:2482-2489.
17. Kose E, An T, Kikkawa A, Matsumoto Y, Hayashi H Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. Biol Pharm Bull 2014, 37:226-231.
18. DiNicolantonio JJ, Lavie CJ, Serebruany VL, O'Keefe JH Statin wars: the heavyweight match-atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med 2013, 125:7-16.
19. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007, 2:1131-1139. Treating to New Targets Investigators.
20. Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009, 54:810-819. CARDS Investigators.
21. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004, 94:882-888.
22. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004, 102:52-60.
23. Guthrie RM, Martin DR The safety of rosuvastatin: effects on renal and hepatic function. Expert Opin Drug Saf 2007, 6:573-581.
24. Stein EA, Vidt DG, Shepherd J, Cain VA, Anzalone D, Cressman MD Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. Atherosclerosis 2012, 221:471-477.
25. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297:1344-1353. METEOR Study Group.
26. Ridker PM, MacFadyen J, Cressman M, Glynn RJ Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein. A secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010, 55:1266-1273.
27. Guder WG, Hofmann W Clinical role of urinary low molecular weight proteins: their diagnostic and prognostic implications. Scand J Clin Lab Invest Suppl 2008, 241:95-98.
28. Sorof J, Berne C, Siewert-Delle A, Jørgensen L, Sager P Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Res Clin Pract 2006, 72:81-87. URANUS Study Investigators.
29. Gaspari F, Perico N, Ruggenenti P, et al. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 1995, 6:257-263.